Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.3% during the third quarter, HoldingsChannel.com reports. The fund owned 94,795 shares of the company’s stock after purchasing an additional 7,255 shares during the quarter. Fisher Asset Management LLC’s holdings in Neurocrine Biosciences were worth $13,307,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Journey Strategic Wealth LLC purchased a new position in shares of Neurocrine Biosciences in the third quarter valued at $254,000. APG Asset Management N.V. boosted its holdings in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. APG Asset Management N.V. now owns 61,008 shares of the company’s stock valued at $8,564,000 after buying an additional 430 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Neurocrine Biosciences in the third quarter valued at approximately $49,000. Handelsbanken Fonder AB boosted its position in Neurocrine Biosciences by 5.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 109,467 shares of the company’s stock valued at $15,367,000 after purchasing an additional 5,500 shares during the period. Finally, Generali Investments Management Co LLC grew its position in shares of Neurocrine Biosciences by 95.0% during the third quarter. Generali Investments Management Co LLC now owns 4,958 shares of the company’s stock worth $696,000 after acquiring an additional 2,415 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Up 1.8%

Shares of NASDAQ NBIX opened at $133.44 on Thursday. Neurocrine Biosciences, Inc. has a 12 month low of $84.23 and a 12 month high of $160.18. The company has a market cap of $13.39 billion, a price-to-earnings ratio of 28.64, a P/E/G ratio of 0.68 and a beta of 0.32. The business has a fifty day simple moving average of $135.00 and a 200-day simple moving average of $140.52.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company had revenue of $805.50 million during the quarter, compared to analysts’ expectations of $804.21 million. During the same period in the prior year, the business posted $1.69 EPS. The company’s revenue for the quarter was up 28.3% compared to the same quarter last year. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on NBIX shares. Royal Bank Of Canada lowered their target price on Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating on the stock in a research report on Thursday, February 12th. Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. lowered their target price on Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 16th. Finally, Truist Financial reduced their price objective on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.05.

Insider Activity

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. The trade was a 20.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Darin Lippoldt sold 4,376 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the sale, the insider directly owned 43,405 shares in the company, valued at approximately $6,929,608.25. This trade represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 46,966 shares of company stock worth $6,474,616 over the last 90 days. 4.80% of the stock is owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.